Compare ECOR & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECOR | PFO |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.3M | 118.6M |
| IPO Year | 2018 | N/A |
| Metric | ECOR | PFO |
|---|---|---|
| Price | $9.62 | $8.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $19.17 | N/A |
| AVG Volume (30 Days) | ★ 79.7K | 30.3K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,032,000.00 | N/A |
| Revenue This Year | $30.85 | N/A |
| Revenue Next Year | $29.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.20 | N/A |
| 52 Week Low | $4.41 | $8.46 |
| 52 Week High | $12.70 | $9.81 |
| Indicator | ECOR | PFO |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 33.64 |
| Support Level | $8.63 | N/A |
| Resistance Level | $9.53 | $9.24 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 4.71 | 25.51 |
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.